Welcome to the Mitchell Center for Neurodegenerative Diseases


Mitchell Center for Neurogenerative Diseases Logo


Mitchell Center at Glance

  • World leader on basic and translational research on disease-relevant polymorphs in Alzheimer’s disease and related dementias.
  • Dedicated strong program in neuroinflammation and resilience to Alzheimer’s disease Neuropathology.
  • Pioneer in functional assays of brain receptors and electrophysiology from banked tissue
  • Over $55,000,000 in NIH Funding
  • $1.6M T32 Training Grant Awarded
    • 25+ Graduate Students
    • 11 Post Doctoral Fellows
  • $616,000 in Foundation Funding
  • 160+ Papers Published in Peer-Reviewed Journals
  • Numerous Undergraduates & Medical Students Trainings
  • Multiple Mentorship Investments


Resources

Message from the Director

Agenor Limon

Welcome to the Mitchell Center for Neurodegenerative Diseases. The Center is housed within the Department of Neurology at UTMB and was established in 2007 thanks to a generous gift from George and Cynthia Mitchell. Our core mission is to promote human health by developing innovative therapeutic approaches for neurodegenerative disorders through investigating and understanding the underlying cellular and molecular pathophysiological mechanisms. Research of the primary faculty of the Mitchell Center covers a wide range of neurodegenerative disorders, with the relative majority of effort focusing on Alzheimer’s Disease and related tauopathies (such as PSP, FTLD, and PART), but also including Parkinson’s Disease and related synucleopathies (such as DLB), Huntington Disease, ALS, autism and epilepsy. The major research focus is on molecular and cellular mechanisms that can be common drivers of these diverse disorders such as protein misfolding, synaptic dysfunction, deficits in synaptic development, altered neurogenesis, neurovascular unit impairments and sex dependency, excitatory/inhibitory imbalance, oxidative stress, DNA damage and repair, insulin resistance, and cognitive resilience. Several innovative therapeutic approaches are also developed and evaluated at the Mitchell Center, including immunotherapy for tau oligomers and other amyloid oligomers, near-infrared light (NIR), calcineurin inhibitors, PLD1 inhibitors, and insulin sensitizers, among others. Testimony of the success of the research at the Mitchell Center is the extensive extramural research support awarded to Center core faculty that currently exceeds $55 million in active grants (including NIH and national foundation grants) with over 160 papers published in peer-reviewed journals. The extraordinary academic environment and research innovation at the Mitchell Center attract trainees from all over the world. Core center faculty are devoted mentors, having trained countless graduate students and postdoctoral fellows that have often moved on to successful independent careers in academia as well as the biotechnology and pharmaceutical fields. At the Mitchell Center, we are all committed to excellency in research and training, and continuing to promote the latest advancements in our knowledge of neurodegenerative diseases with the ultimate goal of developing effective therapies for these devastating disorders.

Sincerely,

Agenor Limon, MSc. Ph.D.

Associate Professor and Vice Chair for Research,
Department of Neurology
Director, Mitchell Center for Neurodegenerative Diseases
Brigadier General and Mrs. Donald B. Wagner
Professorship in Neurodegenerative Disease Research